The discovery that DRs such as CD95 and TNF-related apoptosis-inducing receptor 1 (TRAIL-R1) and TRAIL-R2 are expressed on malignant cells rendered DRs a potential target in cancer therapy and spurred in-depth investigations of DR signaling networks [1–4]. This evidence concerns the gene TNFRSF10A and cancer.